Dyne Therapeutics (DYN) Accounts Payables (2019 - 2026)

Dyne Therapeutics' Accounts Payables history runs 8 years deep, the most recent figure standing at $10.8 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 53.6% year-over-year to $10.8 million; the TTM figure through Mar 2026 stood at $10.8 million (up 53.6% YoY), while the FY2025 annual figure was $8.1 million, up 23.16% from the prior year.
• Accounts Payables was $10.8 million for Q1 2026 at Dyne Therapeutics, up from $8.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $22.9 million in Q4 2023 to a low of $919000.0 in Q3 2022.
• Historically, Accounts Payables has averaged $7.7 million across 5 years, with a median of $7.0 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables sank 87.03% in 2022, then jumped 641.98% in 2025.
• A 5-year view of Accounts Payables shows it stood at $5.3 million in 2022, then jumped by 336.13% to $22.9 million in 2023, then plunged by 71.39% to $6.6 million in 2024, then gained by 23.16% to $8.1 million in 2025, then soared by 33.4% to $10.8 million in 2026.
• The last three Accounts Payables figures came in at $10.8 million (Q1 2026), $8.1 million (Q4 2025), and $12.1 million (Q3 2025), per Business Quant data.